Beth J. Hoffman

Beth J. Hoffman

Company: Origami Therapeutics, Inc.

Job title: CEO


Panel Discussion: TPD in Oncology & Beyond 10:00 am

• Which targets are the right ones to degrade? • Which are the best modalities to pursue (heterobifunctionals, glues) based on target expression, compound distribution, desired PD response? • How do we degrade targets beyond what PROTACs/glues can do? • What diseases could degraders treat in the future? For more information on this session, please download…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.